Title	Trial of feasibility and acceptability of routine low-dose aspirin versus early screening test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial
Authors	Mone, Fionnuala;Mulcahy, Cecilia;McParland, Peter;Breathnach, Fionnuala M.;Downey, Paul;McCormack, Dorothy;Culliton, Marie;Stanton, Alice;Cody, Fiona;Morrison, John J.;Daly, Sean;Higgins, John R.;Cotter, Amanda;Hunter, Alyson;Tully, Elizabeth C.;Dicker, Patrick;Alfirevic, Zarko;Malone, Fergal D.;McAuliffe, Fionnuala M.
Publication date	2018
Original Citation	Mone, F., Mulcahy, C., McParland, P., Breathnach, F., Downey, P., McCormack, D., Culliton, M., Stanton, A., Cody, F., Morrison, J. J., Daly, S., Higgins, J., Cotter, A., Hunter, A., Tully, E. C., Dicker, P., Alfirevic, Z., Malone, F. D. and McAuliffe, F. M. (2018) 'Trial of feasibility and acceptability of routine low-dose aspirin versus Early Screening Test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial', BMJ Open, 8(7), e022056 (9pp). doi: 10.1136/bmjopen-2018-022056
Type of publication	Article (peer-reviewed)
Link to publisher's version	https://bmjopen.bmj.com/content/8/7/e022056 - 10.1136/bmjopen-2018-022056
Rights	© 2018, the Author(s) (or their employer(s). This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. - http://creativecommons.org/licenses/by-nc/4.0/
Download date	2023-05-31 05:16:44

Adverse/Serious Adverse Event	Low dose Aspirin Group 1 N=179	No-aspirin Group 2 N=183	Screen and treat Group 3 N=184
Adverse events			
Vaginal spotting No. (%)	27 (15.1)	18 (9.8)	12 (6.5)
Post-partum haemorrhage No. (%) >500mls >1000mls	 25 (13.0) 7 (3.6%)	 9 (4.9) 1 (0.5)	 12 (6.5) 4 (2.2)
Serious Adverse Events			
NICU admission	9 (5.0)	7 (3.8)	9 (4.9)
Perinatal Death	2 (1.1)	2 (1.1)	2 (1.1)
Maternal admission	18 (10.1)	15 (8.2)	14 (7.6)
Congenital anomaly	3 (1.7)	4 (2.2)	3 (1.6)
Total serious adverse events	32 (17.8)	28 (15.3)	28 (15.2)

Table S3 – Adverse and serious adverse events in all three groups. There may be >1 adverse event or serious adverse event per subject